Mutated GM-CSF-based CAR-T cells targeting CD116/CD131 complexes exhibit enhanced anti-tumor effects against acute myeloid leukaemia.
Aiko HasegawaShoji SaitoShogo NarimatsuShigeru NakanoMika NagaiHideki OhnotaYoichi InadaHirokazu MorokawaIkumi NakashimaDaisuke MoritaYuichiro IdeKazuyuki MatsudaHaruko TashiroShigeki YagyuMiyuki TanakaYozo NakazawaPublished in: Clinical & translational immunology (2021)
GMR CAR-T cell therapy represents a promising strategy for CD116+ R/R AML.
Keyphrases
- cell therapy
- acute myeloid leukemia
- induced apoptosis
- stem cells
- liver failure
- mesenchymal stem cells
- cell cycle arrest
- dendritic cells
- respiratory failure
- cancer therapy
- signaling pathway
- endoplasmic reticulum stress
- drug induced
- intensive care unit
- allogeneic hematopoietic stem cell transplantation
- oxidative stress
- immune response
- hepatitis b virus
- cell proliferation